The GSDME Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the 143B human osteosarcoma cell line, engineered to disrupt the GSDME gene encoding Gasdermin E. This polyclonal knockout model provides a heterogeneous loss-of-function GSDME background, enabling the study of pyroptosis and tumor suppression pathways in a highly metastatic bone cancer context without clonal biases.
The parental 143B cell line, originally derived from the TE85 osteosarcoma, harbors a mutant TP53 gene and displays a highly tumorigenic and metastatic phenotype. These cells are widely used to model osteosarcoma biology and metastatic dissemination, making them a relevant platform for investigating genes involved in cell death and tumor progression. The mutant p53 status further underscores the utility of this model in studying p53-independent cell death mechanisms.
Gasdermin E (GSDME) functions as a key executioner of pyroptotic cell death, acting downstream of caspase-3 cleavage. Upon activation by caspase-3 or caspase-7, the N-terminal fragment of GSDME oligomerizes to form membrane pores, mediating cellular swelling, lysis, and the release of pro-inflammatory cytokines such as IL-1??, IL-18, and HMGB1. GSDME is regulated by upstream signals including chemotherapeutic agents like doxorubicin and cisplatin, as well as TNF and p53, and is frequently silenced in cancers through promoter methylation. It interacts with the autoinhibitory C-terminal domain and potentially with GSDMD, contributing to crosstalk between pyroptosis and other cell death modalities.
In osteosarcoma, GSDME silencing through epigenetic mechanisms is associated with evasion of pyroptotic cell death and enhanced tumor survival. The GSDME Knockout 143B Polyclonal Cells recapitulate this silenced state, providing a powerful tool to dissect the role of GSDME in tumor suppression, metastasis, and drug resistance within a bone cancer context. The model facilitates investigation of alternative cell death pathways, such as apoptosis and necroptosis, that may compensate for GSDME loss and informs therapeutic strategies aimed at restoring pyroptosis sensitivity.
Researchers can employ this knockout model in a variety of functional assays, including Western blotting to confirm GSDME loss, LDH release assays to measure pyroptotic lysis, flow-cytometric analysis of cell death, RT-qPCR for transcript quantification, and ELISA-based detection of IL-1?? and IL-18 secretion. Additional applications encompass caspase-3 activity measurements, immunofluorescence imaging of membrane pore formation, and cell viability, migration, and invasion studies to assess metastatic behavior. This product is suitable for drug sensitivity screens and genetic modifier studies aimed at identifying novel regulators of GSDME-mediated pyroptosis. For further details and personalized support, please contact Ascent Research.
